Psychedelics
What Does Oregon’s Legalization Mean for Me?: Mindshifting Moments #19
Host Margaret Williamson is joined by Shannon Starr of Floresta Retreat. During this episode, the two chat about all of the attributes of psychedelic compounds….
Host Margaret Williamson is joined by Shannon Starr of Floresta Retreat. During this episode, the two chat about all of the attributes of psychedelic compounds.
To add to the fun, we even made a quiz.
More About Floresta Retreat
Psychedelic & Indigenous Medicine Retreat Floresta is a team of clinicians, doctors, coaches, pioneers and those that dare to be the change that is required within mental health and psychiatry. Have you been in therapy for years, tried countless medications or know that there is something more than what is currently being offered within mental health? We are here to facilitate an increase in awareness and consciousness as we blend Western med ical and psychotherapeutic methods with diverse Eastern and Indigenous practices. Working with the medicine of ketamine can allow for clarity, healing, insight and creating with choice. We are here to let you know there is another way. This is a Four-day psychedelic medicine retreat designed to optimize your experience and treatment and allow for lasting transformation We will be immersed in nature which will support a sense of nurturing and wellbeing as we explore non-ordinary states of consciousness and integration.
Transcription
The transcription will be available after the event.
-
Psychedelics7 days ago
Cybin Announces Grant of Additional U.S. Patent in Support of its CYB003 Breakthrough Therapy Program for Major Depressive Disorder
-
Psilocybin6 days ago
Are Shrooms Legal in Oregon: Full Guide
-
Law & Regulation1 week ago
Numinus reports declining revenue as the company restructures
-
Law & Regulation1 week ago
Going concern warnings cloud Xtacy Therapeutics’ shrunk losses
-
Psychedelics7 days ago
Optimi Health Achieves Milestone: Completes In-House Production of MDMA Active Pharmaceutical Ingredient (API)
-
Psychedelics6 days ago
Atai Life Sciences Announces the Publication of Beckley Psytech’s Phase 1 Study of BPL-003 in the Journal of Psychopharmacology
-
Psychedelics7 days ago
Psyence Group’s NASDAQ Listed Associate, Psyence Biomedical Partners with Fluence and iNGENū CRO to Train Research Therapists for Phase IIb Psilocybin Trial
-
Law & Regulation5 days ago
Clearmind signs agreement with Hebrew University for psychedelic compound rights